The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) - Trial NCT06152653
Access comprehensive clinical trial information for NCT06152653 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of California, San Francisco and is currently Recruiting. The study focuses on Asthma,COPD. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of California, San Francisco
Timeline & Enrollment
Phase 4
Nov 21, 2023
Nov 21, 2027
Primary Outcome
Change in mucus plug score
Summary
The goal of this clinical trial is to determine if positive pressure during inspiration will
 improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the
 lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD).
 
 The main questions it aims to answer are:
 
 - Does delivery of aerosolized NAC with positive inspiratory pressure have a greater
 effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.
 
 - Does delivery of aerosolized NAC with positive inspiratory pressure have a greater
 effect on lung function than delivery of NAC without positive pressure.
 
 Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group
 or the NAC via Hillrom-Volara nebulizer group. Participants will each complete 5 treatment
 visits over the course of 30 days. Each treatment visit will consist of two treatments of a
 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the
 nebulization method specific to their group.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06152653
Non-Device Trial